Ostatní
Návod 
CareDx, Inc
CDNA
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
0.8B
Obrat
0B
Zisk
0B
Aktiva
0B
Dluh
0B
ROE
20%
ROA
14%
PE
-41
PS
2
Cena 1R
11-26
⌀ Cena
16.41
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
28-04-2026
Poslední dividenda
Profil
CareDx, Inc. objevuje, vyvíjí a komercializuje diagnostická řešení pro pacienty po transplantaci a pro pečovatele po celém světě. Poskytuje AlloSure Kidney, DNA odvozenou od dárce (dd-cfDNA) roztok pro pacienty po transplantaci ledvin; AlloMap Heart, roztok genové exprese pro pacienty po transplantaci srdce; AlloSure Heart, roztok dd-cfDNA pro pacienty po transplantaci srdce; a AlloSure Lung, roztok dd-cfDNA pro pacienty po transplantaci plic. Společnost také nabízí TruSight HLA, řešení pro typování s vysokým rozlišením na bázi sekvenování nové generace (NGS), Olerup SSP, který se používá k typování alel lidského leukocytárního antigenu (HLA) na bázi technologie sekvenčního primeru, QTYPE, který umožňuje přesnost v typování HLA, a Ottr, software pro řízení pacientů po transplantaci. Kromě toho poskytuje AlloSeq Tx, vysoce rozlišený roztok pro typizaci HLA; AlloSeq cfDNA, kontrolní roztok pro měření dd-cfDNA v krvi; AlloSeq HCT, roztok pro testování chimérismu u příjemců transplantace kmenových buněk; a XynQAPI řešení pro sledování kvality transplantace a řízení pořadníků, stejně jako AlloCare, mobilní aplikaci, která nabízí pacientům orientovaný zdroj pro příjemce transplantace. Společnost nabízí své produkty přímo zákazníkům, jakož i prostřednictvím distributorů a subdistributorů třetích stran. Má licenční smlouvu se společností Illumina, Inc. na distribuci, vývoj a komercializaci produktů a technologií NGS a Cibiltech SAS na komercializaci iBoxu, což je software pro prediktivní analýzu posttransplantační ztráty aloštěpu ledvin. Společnost byla dříve známá jako XDx, Inc. a v březnu 2014 změnila své jméno na CareDx, Inc. Společnost byla založena v roce 1998 a sídlí v jižním San Francisku v Kalifornii.
Sektor
Healthcare
Odvětví
Medical - Diagnostics & Research
Počet zaměstnanců
644
Založení
2014-07-17
Podobné společnosti
$ 6.46
+ $ 0.16
$ 13.69
- $ 0.11
$ 27.52
+ $ 1.16
$ 5.18
+ $ 0.22
$ 10.92
+ $ 0.16
$ 5.36
+ $ 0.23
$ 3.05
+ $ 0.18
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 379.8 | 379.8 | 333.8 | 280.3 | 321.8 | 296.4 | 192.2 | 127.1 | 76.6 | 48.3 | 40.6 | 28.1 | 27.3 | 22.1 | 20.5 | |
| Cost of Revenues | 124.6 | 125.4 | 109.6 | 102.0 | 112.2 | 97.4 | 63.1 | 45.5 | 33.0 | 21.4 | 21.1 | 10.3 | 8.5 | 9.1 | 7.9 | |
| Gross Profit | 255.2 | 254.4 | 224.2 | 178.3 | 209.6 | 199.0 | 129.1 | 81.6 | 43.6 | 27.0 | 19.5 | 17.9 | 18.8 | 13.0 | 12.5 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 108.4 | 100.1 | 86.7 | 84.7 | 86.6 | 82.9 | 92.3 | 72.0 | 65.6 | 67.2 | |
| Cost of Revenues | 36.2 | 31.3 | 28.7 | 28.4 | 28.2 | 27.6 | 28.0 | 25.9 | 26.3 | 24.5 | |
| Gross Profit | 72.2 | 68.7 | 58.0 | 56.3 | 58.4 | 55.3 | 64.3 | 46.1 | 39.3 | 42.7 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 81.9 | 90.4 | 76.5 | 48.9 | 30.7 | 14.5 | 12.4 | 12.4 | 9.3 | 3.8 | 3.2 | 4.8 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 201.2 | 196.4 | 152.2 | 102.7 | 75.4 | 43.6 | 31.7 | 31.9 | 20.6 | 14.9 | 10.7 | 10.1 | |
| Depreciation & Amortization | 20.4 | 20.4 | 19.8 | 19.8 | -0.1 | -0.1 | 1.5 | -0.3 | 4.2 | 3.8 | 2.9 | 0.8 | 0.5 | 0.7 | 1.1 | |
| Total Operating Expenses | 283.6 | 275.4 | 183.4 | 381.7 | 286.8 | 228.7 | 146.8 | 106.1 | 58.1 | 44.1 | 44.3 | 29.9 | 18.8 | 13.9 | 14.9 | |
| Operating Income | -28.4 | -21.0 | 40.8 | -203.4 | -77.2 | -29.7 | -17.7 | -24.5 | -15.6 | -20.3 | -37.3 | -11.9 | 1.3 | -0.9 | -2.3 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 18.3 | 19.0 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 44.9 | 52.4 | ||
| Depreciation & Amortization | 5.3 | 5.2 | 5.1 | 4.9 | 4.7 | 4.9 | 5.0 | 5.2 | 3.0 | 5.0 | ||
| Total Operating Expenses | 78.1 | 66.7 | 69.1 | 69.6 | -16.3 | 65.8 | 71.6 | 65.5 | 63.2 | 71.4 | ||
| Operating Income | -5.9 | 2.0 | -11.1 | -13.4 | 74.7 | -10.5 | -7.3 | -19.3 | -23.9 | -28.8 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 9.2 | 9.2 | 11.8 | 11.9 | 3.8 | 0.2 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 3.8 | 0.0 | 0.3 | -3.7 | 3.7 | 5.9 | 1.9 | 1.6 | 2.1 | 2.1 | 2.7 | |
| Other Expense | 7.3 | -0.1 | 12.1 | 13.2 | 1.0 | -2.4 | -2.0 | 0.6 | -30.0 | -34.3 | -14.7 | -0.1 | 1.4 | -0.5 | 0.0 | |
| IBT | -21.1 | -21.1 | 52.9 | -190.1 | -76.2 | -32.1 | -19.8 | -23.9 | -48.2 | -57.3 | -41.4 | -13.7 | -0.7 | -3.5 | -5.1 | |
| Income Tax Expense | 0.3 | 0.3 | 0.3 | 0.1 | 0.4 | -1.4 | -1.0 | -2.0 | -1.4 | -1.7 | -1.6 | 0.7 | -1.5 | 2.1 | 2.7 | |
| Net Income | -21.4 | -21.4 | 52.5 | -190.3 | -76.6 | -30.7 | -18.7 | -22.0 | -46.8 | -55.5 | -39.5 | -13.7 | 0.8 | -3.5 | -5.1 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 2.0 | 2.0 | 2.4 | 2.8 | 3.1 | 3.0 | 2.8 | 2.9 | 3.2 | 3.2 | ||
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| Other Expense | 2.1 | -0.4 | 2.4 | 3.1 | 3.5 | 3.3 | 2.7 | 2.6 | -94.1 | 5.2 | ||
| IBT | -3.8 | 1.7 | -8.7 | -10.3 | 78.2 | -7.2 | -4.6 | -16.7 | -117.9 | -23.6 | ||
| Income Tax Expense | 0.3 | 0.0 | -0.1 | 0.1 | 0.2 | 0.2 | 0.0 | -0.1 | 0.2 | -0.1 | ||
| Net Income | -4.1 | 1.7 | -8.6 | -10.4 | 78.0 | -7.4 | -4.6 | -16.7 | -118.1 | -23.5 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-3.54 | $-1.44 | $-0.59 | $-0.40 | $-0.52 | $-1.31 | $-2.38 | $-2.39 | $-1.16 | $0.13 | $-0.48 | $-0.69 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-3.54 | $-1.44 | $-0.59 | $-0.40 | $-0.52 | $-1.31 | $-2.38 | $-2.39 | $-1.16 | $0.10 | $-0.48 | $-0.69 | |
| Shares Outstanding | 51.1 | 53.3 | 52.8 | 53.8 | 53.3 | 52.2 | 46.5 | 42.2 | 35.6 | 23.3 | 16.5 | 11.9 | 5.8 | 7.4 | 7.4 | |
| Diluted Shares Outstanding | 51.1 | 53.3 | 56.6 | 53.8 | 53.3 | 52.2 | 46.5 | 42.2 | 35.6 | 23.3 | 16.5 | 11.9 | 9.3 | 7.4 | 7.4 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-2.21 | $-0.43 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-2.21 | $-0.43 | ||
| Shares Outstanding | 51.1 | 52.5 | 54.3 | 55.3 | 54.3 | 52.9 | 52.2 | 51.7 | 53.4 | 54.2 | ||
| Diluted Shares Outstanding | 51.1 | 53.7 | 54.3 | 55.3 | 58.2 | 52.9 | 52.2 | 51.7 | 53.4 | 54.2 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 95.8 | 114.7 | 82.2 | 89.9 | 348.5 | 134.7 | 38.2 | 64.6 | 16.9 | 17.3 | 29.9 | 36.4 | 5.1 | 5.8 | |
| Short Term Investments | 133.1 | 146.0 | 153.2 | 203.2 | 0.0 | 90.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Cash & ST Investments | 228.9 | 260.7 | 235.4 | 293.1 | 348.5 | 224.7 | 38.2 | 64.6 | 16.9 | 17.3 | 29.9 | 36.4 | 5.1 | 5.8 | |
| Accounts Receivable | 66.2 | 64.6 | 51.1 | 66.3 | 59.8 | 34.6 | 24.1 | 9.8 | 3.0 | 2.8 | 2.4 | 2.7 | 2.3 | 1.0 | |
| Inventory | 19.2 | 19.5 | 19.5 | 19.2 | 17.2 | 10.0 | 6.0 | 4.9 | 5.5 | 5.5 | 0.8 | 0.7 | 0.5 | 0.6 | |
| Other Current Assets | 6.3 | 7.1 | 7.8 | 9.2 | 7.9 | 3.8 | 3.6 | 1.8 | 1.4 | 1.2 | 1.3 | 0.5 | 0.3 | 0.2 | |
| Total Current Assets | 320.6 | 351.8 | 313.7 | 387.8 | 433.4 | 273.1 | 71.9 | 81.1 | 26.8 | 26.7 | 34.4 | 40.3 | 8.2 | 7.6 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 91.4 | 68.2 | 88.7 | 114.7 | 95.4 | 95.8 | 93.3 | 82.2 | 76.0 | 87.8 | |
| Short Term Investments | 102.8 | 118.0 | 142.2 | 146.0 | 145.5 | 133.1 | 122.6 | 153.2 | 192.2 | 194.9 | |
| Total Cash & ST Investments | 194.2 | 186.3 | 230.9 | 260.7 | 240.9 | 228.9 | 215.9 | 235.4 | 268.2 | 282.7 | |
| Accounts Receivable | 47.8 | 67.4 | 71.5 | 64.6 | 66.6 | 66.2 | 60.1 | 51.1 | 51.7 | 51.6 | |
| Inventory | 28.3 | 27.9 | 22.9 | 19.5 | 19.3 | 19.2 | 20.1 | 19.5 | 18.0 | 18.8 | |
| Other Current Assets | 29.9 | 25.8 | 24.9 | 7.1 | 7.3 | 6.3 | 6.9 | 7.8 | 7.3 | 7.7 | |
| Total Current Assets | 300.3 | 307.3 | 350.2 | 351.8 | 334.1 | 320.6 | 303.1 | 313.7 | 345.2 | 360.8 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 61.4 | 57.9 | 65.1 | 70.2 | 40.0 | 25.9 | 9.2 | 4.1 | 2.1 | 2.9 | 2.4 | 2.0 | 1.6 | 2.1 | |
| Goodwill | 40.3 | 40.3 | 40.3 | 37.5 | 37.0 | 23.9 | 23.9 | 12.0 | 12.0 | 13.8 | 12.0 | 12.0 | 0.0 | 0.0 | |
| Intangible Assets | 41.9 | 38.2 | 45.7 | 43.1 | 50.2 | 44.4 | 45.5 | 33.3 | 33.1 | 33.1 | 6.7 | 6.7 | 0.0 | 0.0 | |
| Long-Term Investments | 0.6 | 0.0 | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Long-Term Assets | 2.0 | 2.8 | 19.1 | 4.4 | 6.0 | 1.3 | 1.3 | 0.2 | 9.6 | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 | |
| Total Long-Term Assets | 146.2 | 139.2 | 170.9 | 155.1 | 133.3 | 95.4 | 79.8 | 49.6 | 56.8 | 50.1 | 21.3 | 20.8 | 1.7 | 2.3 | |
| Total Assets | 466.8 | 491.1 | 466.8 | 543.0 | 566.6 | 368.5 | 151.7 | 130.7 | 83.6 | 76.7 | 55.6 | 61.1 | 9.9 | 9.9 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 54.9 | 57.3 | 59.1 | 57.9 | 59.8 | 61.4 | 63.0 | 65.1 | 66.3 | 68.2 | |
| Goodwill | 40.3 | 40.3 | 40.3 | 40.3 | 40.3 | 40.3 | 40.3 | 40.3 | 40.2 | 39.7 | |
| Intangible Assets | 33.4 | 36.0 | 37.2 | 38.2 | 40.4 | 41.9 | 43.3 | 45.7 | 46.5 | 43.5 | |
| Long-Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | 0.0 | 0.6 | 0.6 | 0.6 | |
| Other Long-Term Assets | 3.4 | 3.3 | 2.7 | 2.8 | 2.4 | 2.0 | 2.6 | 1.4 | 3.0 | 2.6 | |
| Total Long-Term Assets | 132.0 | 137.0 | 139.4 | 139.2 | 142.9 | 146.2 | 149.3 | 170.9 | 156.0 | 154.0 | |
| Total Assets | 432.3 | 444.3 | 489.6 | 491.1 | 477.0 | 466.8 | 452.4 | 484.6 | 501.2 | 514.8 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 5.9 | 7.7 | 12.9 | 9.9 | 13.3 | 9.7 | 5.5 | 4.7 | 3.4 | 3.1 | 1.6 | 1.1 | 0.6 | 0.6 | |
| Short-Term Debt | 6.1 | 6.1 | 5.9 | 5.6 | 4.0 | 2.0 | 3.0 | 0.2 | 15.7 | 22.8 | 2.9 | 6.0 | 4.5 | 1.5 | |
| Other Current Liabilities | 60.5 | 70.7 | 54.5 | 55.1 | 4.7 | 37.0 | 22.6 | 14.6 | 23.8 | 14.9 | 5.5 | 3.5 | 2.4 | 3.5 | |
| Current Liabilities | 78.3 | 89.4 | 78.1 | 76.0 | 77.3 | 69.2 | 34.8 | 19.5 | 42.9 | 40.8 | 10.2 | 11.1 | 7.6 | 6.4 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 11.6 | 9.9 | 8.1 | 7.7 | 6.2 | 5.9 | 10.0 | 12.9 | 9.0 | 9.9 | |
| Short-Term Debt | 6.4 | 6.3 | 6.2 | 6.1 | 6.1 | 6.1 | 6.1 | 5.9 | 6.0 | 5.8 | |
| Other Current Liabilities | 81.0 | 71.0 | 65.6 | 70.7 | 63.5 | 60.5 | 49.8 | 54.5 | 52.0 | 52.7 | |
| Current Liabilities | 99.0 | 93.2 | 85.3 | 89.4 | 81.4 | 78.3 | 70.2 | 78.1 | 72.7 | 74.5 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 25.4 | 22.3 | 28.3 | 33.4 | 17.4 | 16.1 | 0.0 | 10.5 | 18.3 | 1.1 | 12.9 | 5.5 | 10.9 | 13.4 | |
| Capital Leases | 25.4 | 28.4 | 34.2 | 33.4 | 17.4 | 16.1 | 3.0 | 0.2 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | |
| Def. Tax Liability | 0.1 | 0.2 | 0.1 | 0.0 | 0.4 | 1.3 | 2.0 | 3.0 | 4.9 | 6.1 | 1.4 | 1.7 | 0.0 | 0.0 | |
| Total Liabilities | 202.1 | 112.6 | 205.5 | 112.1 | 100.7 | 90.8 | 52.7 | 34.8 | 89.5 | 57.0 | 26.1 | 19.8 | 160.5 | 157.1 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 21.2 | 22.8 | 24.1 | 22.3 | 23.8 | 25.4 | 26.9 | 28.3 | 29.3 | 30.6 | |
| Capital Leases | 27.6 | 29.1 | 30.3 | 28.4 | 30.0 | 25.4 | 32.9 | 28.3 | 35.2 | 36.4 | |
| Def. Tax Liability | 0.0 | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.0 | 17.9 | 0.1 | 0.1 | |
| Total Liabilities | 121.2 | 116.9 | 110.3 | 112.6 | 203.7 | 202.1 | 196.2 | 223.3 | 107.0 | 109.6 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Retained Earnings | -696.8 | -626.2 | -678.3 | -460.4 | -383.2 | -352.5 | -333.8 | -311.8 | -268.0 | -212.6 | -173.1 | -159.4 | -160.2 | -156.6 | |
| Comprehensive Income | -8.0 | -8.6 | -7.0 | -7.5 | -4.7 | -2.1 | -5.2 | -4.3 | -2.3 | -3.7 | -11.9 | -11.1 | -10.9 | -10.3 | |
| Total Common Equity | 264.7 | 378.4 | 261.3 | 430.9 | 465.9 | 277.7 | 99.0 | 95.9 | -6.1 | 19.5 | 29.5 | 41.3 | -150.7 | -147.2 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | |
| Retained Earnings | -719.0 | -695.2 | -636.6 | -626.2 | -704.3 | -696.8 | -695.5 | -678.3 | -534.2 | -509.9 | |
| Comprehensive Income | -6.0 | -6.1 | -7.1 | -8.6 | -7.2 | -8.0 | -8.1 | -7.0 | -8.7 | -8.5 | |
| Total Common Equity | 311.1 | 327.4 | 379.3 | 378.4 | 273.2 | 264.7 | 256.2 | 261.3 | 394.1 | 405.2 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 31.4 | 28.4 | 34.2 | 39.0 | 17.4 | 16.1 | 3.0 | 0.2 | 34.1 | 23.9 | 15.8 | 11.4 | 15.4 | 14.9 | |
| Book Value | 264.7 | 378.4 | 261.3 | 430.9 | 465.9 | 277.7 | 99.0 | 95.9 | -6.0 | 19.8 | 29.5 | 41.3 | -150.7 | -147.2 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 311.1 | 327.4 | 379.3 | 378.4 | 273.2 | 264.7 | 256.2 | 261.3 | 394.1 | 405.2 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -159.6 | -21.4 | 52.5 | -190.3 | -76.6 | -30.7 | -18.7 | -22.0 | -46.8 | -55.6 | -39.8 | -13.7 | 0.8 | -3.5 | -5.1 | |
| Depreciation & Amortization | 18.2 | 20.4 | 19.8 | 19.8 | 16.0 | 11.9 | 9.5 | 5.5 | 4.2 | 3.8 | 2.9 | 0.8 | 0.5 | 0.7 | 1.1 | |
| Stock-Based Compensation | 49.1 | 34.9 | 66.4 | 49.1 | 46.6 | 36.1 | 23.4 | 22.4 | 7.1 | 1.7 | 2.0 | 1.3 | 0.5 | 0.1 | 0.1 | |
| Change Working Capital | 77.3 | 3.8 | -102.3 | 106.0 | -14.2 | -41.0 | 17.4 | -10.4 | -0.9 | -1.1 | 1.5 | 1.8 | -2.3 | 1.4 | 1.7 | |
| Change In Accounts Receivable | -14.4 | 22.5 | -13.7 | 16.0 | -6.7 | -24.4 | -10.4 | -12.7 | -4.0 | -0.1 | 1.0 | 0.3 | -0.4 | -1.3 | -0.2 | |
| Change In Accounts Payable | -4.0 | 0.8 | -5.1 | 2.9 | -2.1 | 1.8 | 4.4 | 1.4 | -0.2 | 0.3 | -0.6 | 0.5 | 0.5 | 0.0 | -0.1 | |
| Change In Inventories | -0.2 | -5.0 | -1.0 | 0.1 | -2.9 | -6.9 | -3.2 | -1.3 | 0.4 | 1.0 | 0.5 | -0.1 | -0.2 | 0.1 | -0.2 | |
| Other Non-cash Items | 69.7 | 4.3 | 1.8 | -3.6 | 3.2 | 0.3 | 0.3 | 1.8 | 33.9 | 39.0 | 18.2 | 0.0 | -1.4 | 0.4 | 0.4 | |
| Cash from Operations | -14.9 | 0.0 | 0.0 | -18.4 | -25.2 | -19.3 | 33.4 | -2.8 | -4.0 | -14.3 | -16.5 | -9.8 | -3.4 | -0.5 | -1.8 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -4.1 | 1.7 | -8.6 | -10.4 | 78.0 | -1.0 | -4.6 | -16.7 | -118.1 | -23.5 | |
| Depreciation & Amortization | 5.3 | 5.2 | 5.1 | 4.9 | 4.7 | 4.9 | 5.0 | 5.2 | 3.0 | 5.0 | |
| Stock-Based Compensation | 8.1 | 8.4 | 9.4 | 8.9 | 26.2 | 7.2 | 16.4 | 13.3 | 10.0 | 12.7 | |
| Change Working Capital | 12.2 | 18.9 | 3.8 | -31.0 | -86.7 | 0.8 | 2.6 | -19.0 | 96.3 | -2.6 | |
| Change In Accounts Receivable | 5.3 | 19.6 | 4.3 | -6.6 | 1.8 | -0.3 | -6.0 | -9.2 | 0.7 | 0.1 | |
| Change In Accounts Payable | -2.4 | 1.6 | 1.2 | 0.4 | 1.6 | 0.2 | -4.0 | -2.9 | 3.9 | -1.0 | |
| Change In Inventories | 2.0 | -0.3 | -4.1 | -2.7 | -1.3 | 0.5 | 1.0 | -1.3 | -0.7 | 0.7 | |
| Other Non-cash Items | -0.1 | 3.2 | 0.2 | 0.9 | -0.3 | 0.6 | -0.4 | 1.8 | 0.0 | -0.9 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -8.4 | -10.2 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -7.4 | -6.6 | 0.0 | -9.2 | -24.3 | -20.3 | -10.4 | -3.3 | -7.2 | -0.2 | -0.5 | -1.2 | -0.7 | -0.1 | -0.1 | |
| Acquisitions | -2.1 | 0.0 | 0.0 | -6.7 | -0.6 | -15.4 | 0.0 | -18.2 | -0.7 | -5.9 | -20.6 | 0.0 | -0.6 | 0.0 | 0.0 | |
| Investments | -160.0 | -145.9 | -160.3 | -201.2 | -315.1 | -5.5 | -90.0 | -1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.6 | |
| Sales of Investment | 222.9 | 154.7 | 166.9 | 256.0 | 111.6 | 88.9 | 0.0 | 3.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.4 | |
| Other Investing Activities | 20.9 | 0.0 | 0.0 | 1.5 | 0.0 | 0.0 | 0.0 | -3.3 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Cash from Investing | 55.9 | 0.0 | 0.0 | 40.4 | -228.5 | 47.7 | -100.4 | -22.6 | -7.9 | -6.2 | -21.1 | -1.2 | -1.3 | -0.1 | 0.6 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -2.0 | -2.0 | -1.0 | -1.6 | -1.5 | -1.7 | -1.8 | -1.5 | -1.6 | -2.5 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.1 | |
| Investments | -61.6 | -17.1 | -14.8 | -52.5 | -17.7 | -50.0 | -35.5 | -57.7 | -9.0 | -57.7 | |
| Sales of Investment | 28.6 | 31.4 | 39.2 | 55.4 | 17.1 | 37.3 | 25.6 | 86.9 | 49.5 | 60.9 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.5 | -0.9 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 41.4 | -1.5 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -0.2 | -0.2 | -28.8 | -14.4 | -3.9 | -11.5 | -4.5 | -0.1 | -13.0 | |
| Debt Issued | -5.0 | 28.4 | -5.9 | -4.8 | 21.6 | 1.4 | 13.2 | 3.0 | -5.1 | 24.5 | 12.1 | 15.8 | 0.5 | 0.6 | 27.9 | |
| Issuance of Common Stock | 1.8 | 0.0 | 0.0 | 0.0 | 2.4 | 188.9 | 158.1 | 0.0 | 52.9 | 18.3 | 7.9 | 0.2 | 39.2 | 0.0 | 0.0 | |
| Repurchase of Common Stock | -30.9 | -87.8 | -0.5 | -27.5 | -0.6 | 2.1 | 1.4 | 0.8 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.1 | -1.4 | 0.0 | -26.8 | 0.0 | 0.0 | -0.2 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | -7.5 | 0.0 | 0.0 | -2.1 | -6.3 | -3.1 | 5.2 | -0.7 | 52.6 | 16.0 | 20.9 | 15.7 | 1.3 | 0.0 | 17.6 | |
| Cash from Financing | -33.0 | 0.0 | 0.0 | -29.6 | -4.5 | 185.6 | 163.1 | -0.1 | 50.3 | 20.0 | 24.9 | 4.4 | 36.0 | -0.1 | 4.6 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 27.6 | -1.5 | -1.2 | 1.9 | -1.6 | -1.5 | -1.5 | -1.3 | -1.0 | -1.2 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Repurchase of Common Stock | -12.2 | -25.6 | -50.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.5 | -26.0 | -0.8 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.9 | 0.8 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -26.9 | 0.0 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 8.0 | -49.3 | 32.5 | -7.7 | -258.3 | 213.8 | 96.5 | -26.3 | 38.3 | -0.4 | -12.6 | -6.5 | 31.3 | -0.7 | 3.5 | |
| Closing Cash Balance | 95.8 | 66.0 | 115.3 | 82.8 | 90.4 | 348.7 | 134.9 | 38.5 | 64.8 | 16.9 | 17.3 | 29.9 | 36.4 | 5.1 | 5.8 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -26.0 | 23.2 | -20.5 | -26.0 | 19.3 | -0.4 | 2.5 | 11.1 | 6.2 | -11.8 | |
| Closing Cash Balance | 66.0 | 91.4 | 68.8 | 89.3 | 115.3 | 96.0 | 96.4 | 93.9 | 82.2 | 76.6 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -22.3 | 36.1 | 31.6 | -27.6 | -49.6 | -39.6 | 23.1 | -6.1 | -11.2 | -14.5 | -17.1 | -11.0 | -4.1 | -0.6 | -1.9 | |
| Real Free Cash Flow | -71.5 | 1.3 | -34.8 | -76.7 | -96.1 | -75.6 | -0.3 | -28.5 | -18.4 | -16.2 | -19.1 | -12.3 | -4.6 | -0.7 | -2.0 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 19.7 | 36.1 | 8.9 | -28.2 | 20.4 | 10.8 | 17.2 | -16.8 | -10.0 | -12.7 | |
| Real Free Cash Flow | 11.6 | 27.6 | -0.5 | -37.1 | -5.8 | 3.6 | 0.8 | -30.1 | -19.9 | -25.4 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | -41.1 | -37 | 63 |
| P/S | 2.3 | 6.1 | 57.8 |
| P/B | 2.8 | -15 | 29.8 |
| P/FCF | 549.4 | -277 | 549.4 |
| Market cap | $0.8 | $0.9 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 6.4 % | 19 % | 0 % |
| Debt to Income | -129.4 % | -112.5 % | 0 % |
| Debt to Free cash flow | 1732.1 % | -403.6 % | 0 % |
| Interest expense percentage | 0 % | -8.8 % | 2.9 % |
| Current ratio | 3 | 3.3 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | -6.9 % | 222.9 % | 0 % |
| ROA | -4.9 % | -21 % | 0 % |
| CapEx to Revenue | 1.7 % | 3.6 % | 0 % |
| RaD to Revenue | 0 % | 23.7 % | 0 % |
| ROEM | 584,315.4 | 549751 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 67.4 % | 62.4 % | 47.8 % |
| Operating margin | 14.6 % | -23.2 % | 28 % |
| Net margin | 17 % | -35.8 % | 19.8 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 4.6 % | 0 % |
| Dividend payout percentage | 0 % | -10.6 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 53.7 mil | 35.2 mil |
| Employee count | 0.7 tis | 0.4 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
